Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

Compare

1,079 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GPCR Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Structure

Therapeutics, Inc. Sponsored ADR

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GPCR Stock 12 Month Forecast

Average Price Target

$69.57

▲(105.22% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Structure Therapeutics, Inc. Sponsored ADR in the last 3 months. The average price target is $69.57 with a high forecast of $93.00 and a low forecast of $50.00. The average price target represents a 105.22% change from the last price of $33.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","34":"$34","54":"$54","74":"$74","94":"$94"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$93.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,34,54,74,94],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.32,37.91076923076923,42.50153846153846,47.09230769230769,51.683076923076925,56.27384615384616,60.86461538461539,65.45538461538462,70.04615384615386,74.63692307692308,79.22769230769231,83.81846153846155,88.40923076923077,{"y":93,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.32,36.10846153846154,38.89692307692307,41.68538461538461,44.473846153846154,47.26230769230769,50.05076923076923,52.83923076923077,55.6276923076923,58.41615384615384,61.20461538461538,63.99307692307691,66.78153846153845,{"y":69.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.32,34.60307692307693,35.886153846153846,37.16923076923077,38.45230769230769,39.73538461538462,41.01846153846154,42.30153846153846,43.58461538461538,44.86769230769231,46.15076923076923,47.433846153846154,48.71692307692308,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$93.00

Average Price Target$69.57

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ananda Ghosh

H.C. Wainwright

$60

Buy

76.99%

Upside

Reiterated

11/10/25

Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron

Annabel Samimy

Stifel Nicolaus

$50

Buy

47.49%

Upside

Reiterated

11/07/25

Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Patrick Dolezal

LifeSci Capital

$75→$72

Buy

112.39%

Upside

Reiterated

11/06/25

Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position

Andy Hsieh

William Blair

―

Buy

―

Reiterated

11/04/25

Promising Market Potential for Structure Therapeutics' Aleniglipron Driven by Positive Clinical Trials and Strategic AdvantagesWe discuss our expectations in more detail in the full note.

Samantha Semenkow

Citi

$60

Buy

76.99%

Upside

Reiterated

11/03/25

Citi adds 'positive 90-day catalyst watch' on Structure TherapeuticsCiti adds 'positive 90-day catalyst watch' on Structure Therapeutics

Yasmeen Rahimi

Piper Sandler

$93

Buy

174.34%

Upside

Reiterated

10/28/25

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Jonathan Wolleben

Citizens JMP

$87

Buy

156.64%

Upside

Reiterated

09/17/25

Citizens JMP Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $87.00 price target on Structure Therapeutics (NASDAQ: GPCR).

Prakhar Agrawal

Cantor Fitzgerald

$65

Buy

91.74%

Upside

Reiterated

09/17/25

Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Hardik Parikh

J.P. Morgan

―

Buy

―

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR) and Novan (NASDAQ: NOVN)

Evan Seigerman

BMO Capital

$100

Buy

194.99%

Upside

Reiterated

08/11/25

BMO Capital Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

David Risinger

Leerink Partners

$60→$44

Buy

29.79%

Upside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink

Seamus Fernandez

Guggenheim

$92→$90

Buy

165.49%

Upside

Reiterated

08/06/25

Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim

Kaveri Pohlman

Clear Street

$61

Buy

79.94%

Upside

Initiated

07/30/25

Structure Therapeutics initiated with a Buy at Clear StreetStructure Therapeutics initiated with a Buy at Clear Street

Roger Song

Jefferies

$79

Buy

133.04%

Upside

Reiterated

06/05/25

Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating

Terence Flynn

Morgan Stanley

$118→$120

Buy

253.98%

Upside

Reiterated

05/12/25

Structure Therapeutics (GPCR) PT Raised to $120 at Morgan StanleyMorgan Stanley analyst Terence Flynn raised the price target on Structure Therapeutics (NASDAQ: GPCR) to $120.00 (from $118.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ananda Ghosh

H.C. Wainwright

$60

Buy

76.99%

Upside

Reiterated

11/10/25

Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron

Annabel Samimy

Stifel Nicolaus

$50

Buy

47.49%

Upside

Reiterated

11/07/25

Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Patrick Dolezal

LifeSci Capital

$75→$72

Buy

112.39%

Upside

Reiterated

11/06/25

Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position

Andy Hsieh

William Blair

―

Buy

―

Reiterated

11/04/25

Promising Market Potential for Structure Therapeutics' Aleniglipron Driven by Positive Clinical Trials and Strategic AdvantagesWe discuss our expectations in more detail in the full note.

Samantha Semenkow

Citi

$60

Buy

76.99%

Upside

Reiterated

11/03/25

Citi adds 'positive 90-day catalyst watch' on Structure TherapeuticsCiti adds 'positive 90-day catalyst watch' on Structure Therapeutics

Yasmeen Rahimi

Piper Sandler

$93

Buy

174.34%

Upside

Reiterated

10/28/25

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Jonathan Wolleben

Citizens JMP

$87

Buy

156.64%

Upside

Reiterated

09/17/25

Prakhar Agrawal

Cantor Fitzgerald

$65

Buy

91.74%

Upside

Reiterated

09/17/25

Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Hardik Parikh

J.P. Morgan

―

Buy

―

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR) and Novan (NASDAQ: NOVN)

Evan Seigerman

BMO Capital

$100

Buy

194.99%

Upside

Reiterated

08/11/25

BMO Capital Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

David Risinger

Leerink Partners

$60→$44

Buy

29.79%

Upside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink

Seamus Fernandez

Guggenheim

$92→$90

Buy

165.49%

Upside

Reiterated

08/06/25

Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim

Kaveri Pohlman

Clear Street

$61

Buy

79.94%

Upside

Initiated

07/30/25

Structure Therapeutics initiated with a Buy at Clear StreetStructure Therapeutics initiated with a Buy at Clear Street

Roger Song

Jefferies

$79

Buy

133.04%

Upside

Reiterated

06/05/25

Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating

Terence Flynn

Morgan Stanley

$118→$120

Buy

253.98%

Upside

Reiterated

05/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+8.72%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +8.72% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+13.84%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +13.84% per trade.

1 Year

Ananda GhoshH.C. Wainwright

Success Rate

8/8 ratings generated profit

Average Return

+44.45%

reiterated a buy rating 3 days ago

Copying Ananda Ghosh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +44.45% per trade.

2 Years

xxx

Success Rate

8/8 ratings generated profit

Average Return

+44.45%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +44.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GPCR Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GPCR has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GPCR average Analyst price target in the past 3 months is 69.57.

Each month's total comprises the sum of three months' worth of ratings.

GPCR Financial Forecast

GPCR Earnings Forecast

The previous quarter’s earnings for GPCR were -$1.13.

No data currently available

GPCR Sales Forecast

The previous quarter’s earnings for GPCR were $0.00.

GPCR Stock Forecast FAQ

What is GPCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 69.57.

What is GPCR’s upside potential, based on the analysts’ average price target?

Structure Therapeutics, Inc. Sponsored ADR has 105.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GPCR a Buy, Sell or Hold?

Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Structure Therapeutics, Inc. Sponsored ADR’s price target?

The average price target for Structure Therapeutics, Inc. Sponsored ADR is 69.57. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $93.00 ,the lowest forecast is $50.00. The average price target represents 105.22% Increase from the current price of $33.9.

What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?

Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of GPCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

GPCR Analyst Ratings

GPCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

GPCR Analyst Recommendation Trends

GPCR Financial Forecast

GPCR Earnings Forecast

GPCR Sales Forecast

GPCR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts